TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15569840

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 2183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2183
Study: 11717596

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 4312

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 4312
Study: 9741869

Group type: EXPERIMENTAL
Intervention: Outpatient antimicrobial regimens
Number of subjects: 312

Group type: COMPARATOR
Intervention: Inpatient antimicrobial regimens
Number of subjects: 312
Study: 7518775

Group type: EXPERIMENTAL
Intervention: N-acetyl-aspartyl-glutamate (ZY15106)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 15
Study: 2645796

Group type: EXPERIMENTAL
Intervention: Doxepin hydrochloride 150 mg (N = 9)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (N = 10)
Number of subjects: 19
Study: 1092726

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 31746819

Group type: EXPERIMENTAL
Intervention: Balloon Eustachian Tuboplasty (BET)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Balloon Eustachian Tuboplasty with concurrent tympanocentesis
Number of subjects: 30
Study: 30427274

Group type: EXPERIMENTAL
Intervention: Plavix (18.75 mg PO q24h for 7 days)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Generic clopidogrel (18.75 mg PO q24h for 7 days)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Plavix
Number of subjects: 4

Group type: COMPARATOR
Intervention: Generic clopidogrel
Number of subjects: 4
Study: 28571258

Group type: EXPERIMENTAL
Intervention: Immediate loading of implant within two days of insertion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Delayed loading of implant after three months of insertion
Number of subjects: 20
Study: 24983434

Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up appointments
Number of subjects: 24

Group type: COMPARATOR
Intervention: In-person follow-up visits
Number of subjects: 24
Study: 23263240

Group type: EXPERIMENTAL
Intervention: High-sodium diet (300-350 mmol/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low-sodium diet (20 mmol/day)
Number of subjects: 14
Study: 21145244

Group type: EXPERIMENTAL
Intervention: Phrenic nerve infiltration (PNI) with 10 ml of 2% lidocaine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Suprascapular nerve block (SNB) with 10 ml of 0.5% plain bupivacaine
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both groups (PNI and SNB)
Number of subjects: 74
Study: 19653086

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 740
Study: 17955789

Group type: EXPERIMENTAL
Intervention: OROS hydromorphone once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OROS hydromorphone
Number of subjects: 0
Study: 15069400

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 11286448

Group type: EXPERIMENTAL
Intervention: Metronidazole 1g orally, 1 hour preoperatively
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Metronidazole 400mg orally eight hourly for 5 days postoperatively
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 9305320

Group type: EXPERIMENTAL
Intervention: Tolcapone 100 mg three times daily
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Tolcapone 200 mg three times daily
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Tolcapone (both dosages)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 8485014

Group type: EXPERIMENTAL
Intervention: TEB (automated transthoracic electrical bioimpedance method)
Number of subjects: 10

Group type: COMPARATOR
Intervention: ZCG (standard transthoracic impedance cardiography)
Number of subjects: 10
Study: 3732372

Group type: EXPERIMENTAL
Intervention: Fixed combination of hydrochlorothiazide 25 mg and triamterene 50 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Free combination of furosemide 40 mg and triamterene 50 mg
Number of subjects: 30
Study: 29976181

Group type: EXPERIMENTAL
Intervention: Early involvement of the patient's employer in rehabilitation
Number of subjects: 132

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 132
Study: 27502815

Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Back massage
Number of subjects: 105
Study: 24760962

Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (IPost) administered by 4 cycles of 1-minute reocclusion and 1-minute reperfusion, starting 1 minute after opening, followed by stenting.
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control group with immediate stenting after reperfusion.
Number of subjects: 272
Study: 22301933

Group type: EXPERIMENTAL
Intervention: Higher-protein HMF (1.4 g protein/100 mL)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard-protein HMF (1.0 g protein/100 mL)
Number of subjects: 92
Study: 20842617

Group type: EXPERIMENTAL
Intervention: Medication adherence during the maintenance phase
Number of subjects: 1831

Group type: EXPERIMENTAL
Intervention: Insight into illness at week 12
Number of subjects: 1831

Group type: EXPERIMENTAL
Intervention: Cannabis abuse/dependence during the acute phase
Number of subjects: 1831

Group type: EXPERIMENTAL
Intervention: Work impairment
Number of subjects: 1831

Group type: EXPERIMENTAL
Intervention: Higher CGI hallucinations/delusions at baseline
Number of subjects: 1831
Study: 18394319

Group type: EXPERIMENTAL
Intervention: SRP plus 1 CHX chip
Number of subjects: 82

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 82
Study: 16170294

Group type: EXPERIMENTAL
Intervention: Serum progesterone (P) levels on the day of human chorionic gonadotropin (hCG) administration
Number of subjects: 460
Study: 12429069

Group type: EXPERIMENTAL
Intervention: Spiral-CT screening (A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: X-ray screening (B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No screening (C)
Number of subjects: 0
Study: 10490789

Group type: EXPERIMENTAL
Intervention: (‐)‐HCA (3.0 g/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8526959

Group type: EXPERIMENTAL
Intervention: Continuous monitoring via pulsoximeter and capnometer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Regular assessments of respiratory rate and blood gas analysis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patient-controlled intravenous analgesia with sufentanil (15 micrograms initial bolus)
Number of subjects: 30
Study: 1638578

Group type: EXPERIMENTAL
Intervention: Cefoxitin (CFX)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Gentamicin-Clindamycin (G/C)
Number of subjects: 51
Study: 6707245

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Thioridazine plus either social skills training or holistic health therapy
Number of subjects: 20
Study: 30853647

Group type: EXPERIMENTAL
Intervention: Purgative Manna drops (5 drops/kg divided into three doses per day for three days)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Purgative Manna drops
Number of subjects: 445

Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 445
Study: 29903598

Group type: EXPERIMENTAL
Intervention: Cognitive functional therapy
Number of subjects: 148

Group type: COMPARATOR
Intervention: Combined manual therapy and motor control exercises
Number of subjects: 148
Study: 27601883

Group type: EXPERIMENTAL
Intervention: Gratisovir (400 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Grateziano (400 mg daily)
Number of subjects: 50
Study: 24627237

Group type: EXPERIMENTAL
Intervention: Docetaxel 45 mg/m² with bolus and 44 h infusion of 5-Fu/Lv (arm T)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Irinotecan 180 mg/m² with bolus and 44 h infusion of 5-Fu/Lv (arm C)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both regimens after crossover
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Chemotherapy in advanced GC
Number of subjects: 81
Study: 22586106

Group type: EXPERIMENTAL
Intervention: Genetic variability of the gene encoding PKCα (PRKCA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identified genetic variant
Number of subjects: 0
Study: 19680704

Group type: EXPERIMENTAL
Intervention: Lupin protein
Number of subjects: 43

Group type: COMPARATOR
Intervention: Casein (control)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Lupin protein vs Casein
Number of subjects: 43
Study: 19062728

Group type: EXPERIMENTAL
Intervention: Zoledronic acid combined with local radiotherapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 45
Study: 15695781

Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET imaging in patients with FTD
Number of subjects: 29
Study: 14660711

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) administration
Number of subjects: 22
Study: 10469748

Group type: EXPERIMENTAL
Intervention: Bilateral prophylactic oophorectomy
Number of subjects: 122
Study: 8782340

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: Overall and arm size data
Number of subjects: 1136
Study: 1723463

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 40
Study: 6192505

Group type: EXPERIMENTAL
Intervention: Tendamistate 100 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tendamistate 200 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31962191

Group type: EXPERIMENTAL
Intervention: Foot strengthening program (IG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 28
Study: 31649125

Group type: EXPERIMENTAL
Intervention: Intravenous microtracer of 10 µg [14C]nemiralisib
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Inhaled nonradiolabeled 1000 µg dose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral 800 µg dose of [14C]nemiralisib
Number of subjects: 6
Study: 27612466

Group type: EXPERIMENTAL
Intervention: B group vitamin
Number of subjects: 71
Study: 25395210

Group type: EXPERIMENTAL
Intervention: NSC 631570 administered i.v. in a single therapeutic dose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NSC 631570 administered i.v. in an outpatient setting
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Moderate physical exercise (50 slow squats)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NSC 631570 administered in an inpatient setting
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Active participants after drug injection
Number of subjects: 8
Study: 24421054

Group type: EXPERIMENTAL
Intervention: β‐glucan 10 mg capsules administered twice a day for 10 days
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: β‐glucan
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 21822034

Group type: EXPERIMENTAL
Intervention: Juice Plus+® (micronutrient concentrate)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 19144772

Group type: EXPERIMENTAL
Intervention: CRA13 1-80 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: CRA13 40 mg with food
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: CRA13 40-80 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 17615477

Group type: EXPERIMENTAL
Intervention: Oropharyngeal sensory stimulation for 1020 minutes, 1 time per day for 2 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study: 15282117

Group type: EXPERIMENTAL
Intervention: Heavy alcohol intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 12642692

Group type: EXPERIMENTAL
Intervention: Thalidomide monotherapy (200 to 1,200 mg/day)
Number of subjects: 63
Study: 9457020

Group type: EXPERIMENTAL
Intervention: Headgear (combination)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Functional appliance (modified bionator)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 166
Study: 10172461

Group type: EXPERIMENTAL
Intervention: Budesonide (inhaled corticosteroid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide (once-daily administration in dry powder form via Turbuhaler)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 0
Study: 1761121

Group type: EXPERIMENTAL
Intervention: Heparin (low-dose continuous administration)
Number of subjects: 234

Group type: COMPARATOR
Intervention: No Heparin
Number of subjects: 234
Study: 6813959

Group type: EXPERIMENTAL
Intervention: Trimipramine (25 mg, two tablets)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (two tablets)
Number of subjects: 12
Study: 31350027

Group type: EXPERIMENTAL
Intervention: SAVR
Number of subjects: 2028

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 2028
Study: 30756339

Group type: EXPERIMENTAL
Intervention: Iloprost inhalation (20 µg)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study: 27664095

Group type: EXPERIMENTAL
Intervention: Intragastric Balloon (IGB)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard Medical Care (SMC)
Number of subjects: 115
Study: 25660925

Group type: EXPERIMENTAL
Intervention: Ticagrelor therapy
Number of subjects: 18624

Group type: COMPARATOR
Intervention: Clopidogrel therapy
Number of subjects: 18624
Study: 24326597

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Non-nucleoside reverse transcriptase inhibitor (NNRTI)
Number of subjects: 185
Study: 22166801

Group type: EXPERIMENTAL
Intervention: Grilled meat
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Well or very well‐done meat
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: 2‐amino‐1‐methyl‐6‐phenyl‐imidazo[4,5‐b]pyridine (PhIP)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Benzo[a]pyrene
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Total mutagenic activity
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Total iron (diet and supplements)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Iron from supplements
Number of subjects: 1008
Study: 20467605

Group type: EXPERIMENTAL
Intervention: Rigid synthetic resorbable barriers (Inion)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Granular anorganic bovine bone (Bio‐Oss)
Number of subjects: 10
Study: 17721018

Group type: EXPERIMENTAL
Intervention: hANP administration
Number of subjects: 124

Group type: COMPARATOR
Intervention: non-hANP group
Number of subjects: 124
Study: 15206993

Group type: EXPERIMENTAL
Intervention: Grapefruit juice 200 ml
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 10
Study: 12375798

Group type: EXPERIMENTAL
Intervention: Topoisomerase I inhibitors in nonplatinum combinations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Platinum-based combinations
Number of subjects: 0
Study: 9661000

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pefloxacin 800 mg
Number of subjects: 12
Study: 8619366

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.05 IU/kg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.10 IU/kg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.20 IU/kg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2527054

Group type: EXPERIMENTAL
Intervention: Acitretin plus bath PUVA (trimethylpsoralen bath + UVA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Etretinate plus bath PUVA
Number of subjects: 34
Study: 344042

Group type: EXPERIMENTAL
Intervention: Bromocryptine (average daily dose 71 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bromocryptine
Number of subjects: 23
Study: 31278091

Group type: EXPERIMENTAL
Intervention: Training and implementation of essential interventions for CVD prevention in primary healthcare (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (n=10)
Number of subjects: 20
Study: 28118281

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Spironolactone addition
Number of subjects: 106
Study: 26387012

Group type: EXPERIMENTAL
Intervention: Hypothermia treatment for neonatal encephalopathy
Number of subjects: 124
Study: 23279630

Group type: EXPERIMENTAL
Intervention: Motivational interviewing and physical exercise programme
Number of subjects: 56

Group type: COMPARATOR
Intervention: Regular activities in the centre (Control)
Number of subjects: 56
Study: 21864816

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 3602

Group type: COMPARATOR
Intervention: UFH plus GPI
Number of subjects: 3602

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3602

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 3602

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 3602

Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 3602
Study: 18988892

Group type: EXPERIMENTAL
Intervention: LY518674 (100 microg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 17943569

Group type: EXPERIMENTAL
Intervention: Low-dose theophylline
Number of subjects: 284

Group type: COMPARATOR
Intervention: Montelukast
Number of subjects: 284
Study: 15507932

Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 46
Study: 11794965

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 0
Study: 9142061

Group type: EXPERIMENTAL
Intervention: Monovalent live attenuated (RA27/3 strain) rubella vaccine
Number of subjects: 546

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 546
Study: 7959143

Group type: EXPERIMENTAL
Intervention: Decreased fetal movement (study group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normal fetal movement (control group)
Number of subjects: 200
Study: 3664944

Group type: EXPERIMENTAL
Intervention: Preoperative doxorubicin instillation
Number of subjects: 51

Group type: COMPARATOR
Intervention: TUR alone (Control)
Number of subjects: 51
Study: 31217148

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BVS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Everolimus-eluting metallic stents (EES)
Number of subjects: 70
Study: 29164723

Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 27264217

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (Resolute Integrity) or everolimus-eluting stents (Promus Element)
Number of subjects: 798
Study: 24256334

Group type: EXPERIMENTAL
Intervention: Thymus honey mouthwashes
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lemon candy (standard treatment)
Number of subjects: 120
Study: 23919857

Group type: EXPERIMENTAL
Intervention: E2V/DNG (oestradiol valerate/dienogest) administered in a dynamic dosing regimen (26/2 regimen)
Number of subjects: 441

Group type: COMPARATOR
Intervention: EE/LNG (ethinyloestradiol/levonorgestrel) in a monophasic regimen (21/7 regimen)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: E2V/DNG
Number of subjects: 441
Study: 21534684

Group type: EXPERIMENTAL
Intervention: Randomized experiment
Number of subjects: 588

Group type: COMPARATOR
Intervention: Regression discontinuity design
Number of subjects: 588
Study: 18978610

Group type: EXPERIMENTAL
Intervention: Resisted sled towing with approximately 10% body mass (BM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Resisted sled towing with approximately 20% body mass (BM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Unresisted sprints
Number of subjects: 10
Study: 16263828

Group type: COMPARATOR
Intervention: 0.24 mg/kg x wk GH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.37 mg/kg x wk GH
Number of subjects: 0
Study: 12748212

Group type: EXPERIMENTAL
Intervention: Pharmacist led intervention to improve drug compliance
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Model based on medical history, weight, presence of oedema, and lower blood pressure
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Model with addition of beta blockers
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Model with addition of NYHA class
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Model with data on quality of life
Number of subjects: 152
Study: 10808985

Group type: EXPERIMENTAL
Intervention: Interactive computer intervention
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Standard teacher-led intervention
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Long-term follow-up survey
Number of subjects: 209
Study: 8820427

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg) + Quinidine (100 mg daily)
Number of subjects: 20
Study: 1602035

Group type: EXPERIMENTAL
Intervention: Meswak
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional toothbrush
Number of subjects: 0
Study: 3893701

Group type: EXPERIMENTAL
Intervention: Ibuprofen-codeine phosphate combination
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Zomepirac
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 31320282

Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 0
Study: 29727366

Group type: EXPERIMENTAL
Intervention: Patient-directed music intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual ICU care
Number of subjects: 0